Cubeddu, MD, Harvard-trained interventional cardiologist and President of the NCH Rooney Heart Institute, represents the ...

CroíValve is making inroads in the tricuspid regurgitation (TR) treatment market currently occupied by Abbott and Edwards.

With Edwards and Abbott making recent waves in the tricuspid regurgitation (TR) treatment space, CroíValve hopes to pave its ...

The US Food and Drug Administration (FDA) has granted approval for Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system for leaky tricuspid heart valves. This device is specifically ...

The Society of Thoracic Surgeons (STS) has published three new online calculators that spell out personalized risks for ...

Growing evidence indicates that severe tricuspid regurgitation (TR) is independently associated with adverse clinical outcomes. The prognostic benefit of isolated TR surgery remains unclear ...

This is a first-of-its-kind device to repair a leaky tricuspid valve known as tricuspid regurgitation or TR. “Our team has been working with this device for many years,” said interventional ...

Medical researchers have performed a successful transcatheter tricuspid valve repair procedure with a groundbreaking catheter. UC Davis Health cardiology team members are among the first in the ...

The expanding use of transcatheter technologies has changed the landscape in the treatment of valvular disease in adult cardiac patients, with valve surgery rapidly shifting to more complex ...

New mitral and tricuspid valve treatments are attracting strong demand, but analysts said transcatheter aortic valve replacement sales were shy of expectations.

April 25, 2024 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS is $0.66, expectations were $0.64.

UC Davis Health cardiology team members are among the first in the country to treat patients with tricuspid regurgitation, or a leaky heart valve, by using a groundbreaking catheter. The minimally ...